Sutro Biopharma (STRO) Income from Continuing Operations (2017 - 2025)

Sutro Biopharma has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 46755000.0 for Q4 2025.

• Income from Continuing Operations for Q4 2025 came in at 46755000.0, down 130.64% year-over-year; the trailing twelve-month figure through Dec 2025 was 180436000.0 (down 7418.17% YoY), and the FY2025 annual result was 191079000.0, down 7861.62% from the prior year.
• Income from Continuing Operations came in at 46755000.0 for Q4 2025 at Sutro Biopharma, up from 56857000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 152618000.0 in Q4 2024 to a low of 65325000.0 in Q1 2025.
• The 5-year median for Income from Continuing Operations is 38324500.0 (2021), against an average of 25184100.0.
• Across the five-year window, Income from Continuing Operations tumbled 322.82% in 2022 and soared 391.29% in 2024, its largest moves.
• Sutro Biopharma's Income from Continuing Operations stood at 38125000.0 in 2021, then gained by 9.26% to 34594000.0 in 2022, then surged by 189.8% to 31065000.0 in 2023, then jumped by 391.29% to 152618000.0 in 2024, then tumbled by 130.64% to 46755000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 46755000.0 (Q4 2025), 56857000.0 (Q3 2025), and 11499000.0 (Q2 2025), per Business Quant data.